Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Year: 2023
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: European Urology
Authors: Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, Arlene O. Siefker-Radtke, Jakub Zolnierek, Tibor Csoszi, Sang Joon Shin, Se Hoon Park, Vagif Atduev, Mahmut Gumus, Yu-Li Su, Saziye Burcak Karaca, Hernán Javier Cutuli, Mehmet A.N. Sendur, Liji Shen, Karen O'Hara, Chinyere E. Okpara, Sonia Franco, Blanca Homet Moreno, Petros Grivas, Yohann Loriot
Institutions: National Cancer Center Hospital East, Erasmus MC Cancer Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, The University of Texas MD Anderson Cancer Center, Yonsei University, Yonsei University Health System, Samsung Medical Center, Sungkyunkwan University, Federal Medical-Biological Agency, Istanbul Medeniyet University, Chang Gung University, Kaohsiung Chang Gung Memorial Hospital, Instituto de Diagnóstico e Investigaciones Metabólicas, Ankara Yıldırım Beyazıt University, Merck & Co., Inc., Rahway, NJ, USA (United States), Eisai (United Kingdom), University of Washington, Fred Hutch Cancer Center, Université Paris-Saclay, Institut Gustave Roussy
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4387190801